Shares of Theravance Biopharma TBPH plunged 26% after the company announced the failure of the late-stage CYPRESS study ...

Theravance Biopharma said it is chopping its workforce by 50% and launching a review of strategic alternatives designed to maximize shareholder value, after its sole rare disease pipeline candidate, ...